Pan Pantziarka

Program Director

Back to Speakers

Dr Pan Pantziarka is the Program Director for Drug Repurposing at the Anticancer Fund and the coordinator of the Repurposing Drugs in Oncology (ReDO) project (, an international collaboration between the Anticancer Fund and the US not-for-profit GlobalCures. In addition to publishing papers on specific non-cancer drugs with the potential to be repurposed for oncological use, the ReDO project is engaged on cancer policy work related to drug licensing and similar issues. He is also on the faculty of the International School of Metronomic Chemotherapy. Other research interests include the rare genetic cancer condition Li Fraumeni Syndrome (LFS) and the development of computational models of tumour growth.

Pan is also the co-founder and Chairman of the George Pantziarka TP53 Trust (, a UK-based patient advocacy and support organisation for sufferers LFS.
Selected Recent Publications include:

Pantziarka P, Verbaanderd C, Sukhatme V, et al. (2018). ReDO_DB: the repurposing drugs in oncology database.  Ecancermedicalscience 2018; 12 886.
Pantziarka P., Pirmohamed M., Mirza N. (2018). New uses for old drugs. BMJ (Clinical research ed.) 361:k2701.
Pantziarka P, Sukhatme V, Crispino S, et al. (2018) Repurposing drugs in oncology (ReDO)—selective PDE5 inhibitors as anticancer agents. Ecancermedicalscience 2018;12:1–22.
Pantziarka P, Bouche G., Sullivan R et al. (2017). Perioperative therapies – Enhancing the impact of cancer surgery with repurposed drugs. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 43:1985–1988.
Verbaanderd C, Meheus L, Huys I and Pantziarka P (2017) Repurposing Drugs in Oncology: Next Steps. Trends in cancer, 3(8), pp. 543–546.
Pantziarka P (2017) Scientific advice – is drug repurposing missing a trick? Nature reviews. Clinical oncology, 14(8), pp. 455–456.
Pantziarka P, Bouche G, Sukhatme V, Meheus L, et al. (2016) Repurposing Drugs in Oncology (ReDO)-Propranolol as an anti-cancer agent. Ecancermedicalscience, 10, p. 680.
Pantziarka P (2016) Emergent properties of a computational model of tumour growth. PeerJ, 4, p. e2176.
Pantziarka P (2015) Primed for cancer: Li Fraumeni Syndrome and the pre-cancerous niche. Ecancermedicalscience, 9, p. 541.
Pantziarka P., Bouche G., Meheus L., et al. (2015). Repurposing drugs in your medicine cabinet: untapped opportunities for cancer therapy? Future oncology (London, England) 11:181–4.